ARK Genomic Revolution ETF vs Eli Lilly And Co — how do they compare? ARK Genomic Revolution ETF trades at $44.48, while Eli Lilly And Co trades at $1,218.2 (market cap $1.08T). The key difference: Eli Lilly And Co pays a 0.57% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | LLY | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $44.55 | $1.24K |
52-Week Low | $24.02 | $639.43 |
Market Cap | — | $1.08T |
Enterprise Value | — | $1.13T |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Trailing returns across standard periods
Latest headlines on both assets
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →